We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
The most recent trading session ended with AbbVie (ABBV - Free Report) standing at $187.66, reflecting a +0.17% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 0.83%.
The drugmaker's shares have seen a decrease of 0.4% over the last month, surpassing the Medical sector's loss of 2.31% and falling behind the S&P 500's gain of 5.17%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company's upcoming EPS is projected at $3.24, signifying a 22.26% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $14.98 billion, indicating a 3.56% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $12.28 per share and revenue of $60.04 billion. These totals would mark changes of +21.34% and +6.58%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. AbbVie currently has a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 15.25. This valuation marks a premium compared to its industry's average Forward P/E of 13.69.
It is also worth noting that ABBV currently has a PEG ratio of 1.24. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.24 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 30, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
The most recent trading session ended with AbbVie (ABBV - Free Report) standing at $187.66, reflecting a +0.17% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 0.83%.
The drugmaker's shares have seen a decrease of 0.4% over the last month, surpassing the Medical sector's loss of 2.31% and falling behind the S&P 500's gain of 5.17%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company's upcoming EPS is projected at $3.24, signifying a 22.26% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $14.98 billion, indicating a 3.56% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $12.28 per share and revenue of $60.04 billion. These totals would mark changes of +21.34% and +6.58%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% lower. AbbVie currently has a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 15.25. This valuation marks a premium compared to its industry's average Forward P/E of 13.69.
It is also worth noting that ABBV currently has a PEG ratio of 1.24. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.24 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 30, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.